Author:
Vermeire Severine,Sands Bruce E,Tilg Herbert,Tulassay Zsolt,Kempinski Radoslaw,Danese Silvio,Bunganič Ivan,Nitcheu Josianne,Santo Julien,Scherrer Didier,Biguenet Sophie,Ehrlich Hartmut J,Steens Jean-Marc,Gineste Paul,Sandborn William J
Subject
Gastroenterology,Hepatology
Reference19 articles.
1. Ulcerative colitis;Ordás;Lancet,2012
2. Ulcerative colitis-diagnostic and therapeutic algorithms;Kucharzik;Dtsch Arztebl Int,2020
3. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study;Danese;Lancet Gastroenterol Hepatol,2021
4. Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study—(PURSUIT-J study);Hibi;J Gastroenterol,2017
5. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials;Rubin;Lancet Gastroenterol Hepatol,2022
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献